Splash Image
About Us

Management Team

Leading Discoveries in Therapeutic Antibodies

Bringing together industry experts, blue-chip investors, and a cross-disciplinary team of top scientists in antibody drug discovery and disease biology, we’re translating therapeutics into the clinic. Meet our Management Team, headquartered in the MaRS Discovery District of Toronto:

Stefan Larson, PhD

Stefan Larson, PhD, CEO

Stefan Larson, PhD

Stefan Larson, PhD

CEO

Stefan Larson is an Entrepreneur-in-Residence with Versant Ventures, and co-founded Northern Biologics in his role as President of Blueline Bioscience, a Toronto-based biotechnology incubator.

Prior to joining Versant, Stefan was the co-founding CEO of Tornado Medical Systems, a revenue stage scientific and medical instruments company with product lines in high performance Raman spectroscopy and optical coherence tomography. He began his professional career as a management consultant with McKinsey & Company, serving clients in the healthcare and technology sectors as an Associate Principal in the firm.

Stefan received his PhD in Biophysics from Stanford University, where he studied as a James H. Clark Graduate Fellow. He received his MSc in Molecular and Medical Genetics from the University of Toronto.

 

Jeanne Magram, PhD

Jeanne Magram, PhD, CSO

Jeanne Magram, PhD

Jeanne Magram, PhD

CSO

Jeanne Magram is the founding Chief Scientific Officer of Northern Biologics.

Prior to joining Northern Biologics, Jeanne served as the Site Head for Pfizer’s Centers for Therapeutic Innovation (CTI), New York, a model partnership between Pfizer and academic medical centers designed to accelerate the translation of innovative discoveries into differentiated new medicines to treat diseases of pressing unmet medical need. Prior to CTI, Jeanne was Vice President, Immunology & Inflammation Research at Boehringer Ingelheim, overseeing a department committed to drug discovery to address unmet medical needs in autoimmune disease. In this role, she delivered several candidates into clinical testing. Jeanne was also an Associate Director of GPCR Drug Discovery at OSI Pharmaceuticals after OSI’s acquisition of Cadus Pharmaceutical’s Drug Discovery programs, and spent over five years at Hoffmann-La Roche focused on using model systems to understand the pathophysiology of disease and to identify new therapies.

Jeanne completed her postdoctoral training in the laboratory of Nobel Laureate Dr. J. Michael Bishop at the University of California, San Francisco and obtained her PhD in the laboratory of Dr. Frank Costantini in Genetics and Development at Columbia University.

Robert Wasserman, MD

Robert Wasserman, MD, CMO

Robert Wasserman, MD

Robert Wasserman, MD

CMO

Dr. Wasserman is the Chief Medical Officer at Northern Biologics as of December, 2016. Dr. Wasserman’s expertise lies in oncology translational medicine, including preclinical, clinical, biomarker and companion diagnostic drug development.

From May 2014 through November 2016, Dr. Wasserman was responsible for leading the medical strategy for Oncology and Malignant Hematology as the Global Therapeutic Area Head for Covance, the CRO division of LabCorp. He was the leader for the physician group that monitors global and regional Oncology trials for clients. He led the cross -business unit team responsible for educating employees and promoting their Immuno-Oncology expertise and capabilities as part of a corporate strategic initiative.

Before joining Covance, Dr. Wasserman spent 15 years in the pharmaceutical industry, most recently at Hoffmann-La Roche as Site Head of Academic Alliances, Pharma Research and Early Development (pRED) for the Translational Clinical Research Center. He also served as Vice President and Personalized Healthcare Strategic Expert for Roche pRED Oncology, where he was responsible for the personalized healthcare strategy across the preclinical and early clinical development portfolio. In addition, as Vice President and Global Head, Translational Medicine for Roche pRED Oncology, he was responsible for bridging discovery and clinical research through the development of translational medicine strategies, conducting early-phase trials, and supporting the personalized healthcare objectives of the organization. Prior to his employment at Roche, he was the Deputy Director of the Oncology Biomarker group aat Novartis after starting his pharmaceutical career at Merck.

Dr. Wasserman earned his M.D. from Johns Hopkins University School of Medicine, and completed his Pediatric Residency and Pediatric Hematology-Oncology fellowship training at The Children’s Hospital of Philadelphia, University of Pennsylvania. After completing his training, he stayed on as an Assistant Professor for nine years.

Rahul Ballal, PhD

Rahul Ballal, PhD, CBO

Rahul Ballal, PhD

Rahul Ballal, PhD

CBO

Rahul joined as Chief Business Officer of Northern Biologics in May 2016. Prior to Northern, Rahul was VP of Business Development at Flexion Therapeutics (FLXN) where he led the company through several key transactions, including a $125MM strategic manufacturing partnership with Patheon UK. Prior to Flexion, he ran business development at the Broad Institute where he completed several out-licensing deals, including the one that founded Verastem (VSTM). Rahul started his career in Silicon Valley as the founder/CEO of Redmind, a venture backed data analytics startup that he sold to Ikimbo Inc., in 2002.

Rahul has a PhD in cancer biology from Georgetown School of Medicine, an MS in bioinformatics from Johns Hopkins, and a BA from Brown University. He also completed his Kauffman Fellowship (Class 15) at Novartis Venture Funds.

Judit Anido, PhD, MBA

Judit Anido, PhD, MBA, VP Operations and Corporate Affairs

Judit Anido, PhD, MBA

Judit Anido, PhD, MBA

VP Operations and Corporate Affairs

Judit joined Northern Biologics as VP of Operations and Corporate Affairs in June 2017. Previously, Judit was co-founder of Mosaic Biomedicals, a Barcelona-based company that develops personalized cancer treatments with a dual mechanism of action targeting cancer stem cells and the tumor’s immune system. As Mosaic’s CEO, Judit led the growth of the company until its merger with Northern in 2016. Prior to Mosaic, Judit was Associate at the Pipeline and Portfolio Planning team collaborating with the Oncology & Hemathology Franchise at Genentech Inc. (CA, US).

Judit holds a Master in Business Administration (MBA) from Duke University (NC, US) with a certification in Health Sector Management and concentration in Entrepreneurship and Innovation. In addition, she received her PhD from the University of Barcelona (Spain) and has 10+ years of scientific career in translational oncology at the Vall d’Hebron Institute of Oncology (Spain). Judit is recipient of merit-based scholarships from the Spanish Association Against Cancer (AECC), Rafael del Pino Foundation, Caja Madrid Foundation and Duke University’s Julian Connally Scholarship.